Nehal Lakhani

12PUBLICATIONS
115CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 08, 2026
Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

|Mar 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Francois Ghiringhelli, Richard Kim, Teresa Macarulla

|Nov 03, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

David H Aggen, Meredith McKean, Jean H Hoffman-Censits

|Jan 12, 2025
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.

Nehal J Lakhani, Daphne Stewart, Debra L Richardson

|Oct 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson

|Sep 14, 2024
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors.

Nehal J Lakhani, Howard Burris, Wilson H Miller

Pageof 2

Frequent Collaborators

2 joint publications

Jayakumar Mani

2 joint publications

Diwakar Davar

2 joint publications

Anne Paccaly

2 joint publications

Kyriakos P Papadopoulos